Symptomatic fever management in children: A systematic review of national and international guidelines

Short title:

Fever management: a systematic review of guidelines

Cari Green¹, Hanno Kraft¹, Gordon Guyatt², David Martin^{1,3}

¹ Gerhard Kienle Chair, Health Department, University of Witten/Herdecke, Herdecke, Germany

² Departments of Health Research Methods, Evidence and Impact and Medicine at McMaster University, Hamilton, Canada,

³ University Children's Hospital, Tübingen University, Tübingen, Germany

* Corresponding author

E-mail: david.martin@uni-wh.de (DM)

Keywords: fever, children, antipyretic, guideline, review

Source of funding: No funding was requested for this study.

Financial disclosure: The authors have no financial ties relevant to this article.

Conflict of interest: The authors have no conflicts of interest.

Abstract

Introduction: A comprehensive assessment of the recommendations made by clinical practice guidelines (CPGs) on symptomatic fever management in children has not been carried out.

Methods: Searches were conducted on Pubmed, google scholar, pediatric society websites and guideline databases to locate CPGs from each country. Rather than assessing overall guideline quality, the level of evidence for each recommendation was evaluated according to criteria of the Oxford Centre for Evidence-Based Medicine (OCEBM). A GRADE assessment was undertaken to assess the body of evidence related to a single question: the threshold for initiating antipyresis.

Results: 74 guidelines were retrieved. Recommendations for antipyretic threshold, type and dose; ambient temperature; dress/covering; activity; fluids; nutrition; proctoclysis; external applications; complementary/herbal recommendations; media; and age-related treatment differences all varied widely. OCEBM evidence levels for most recommendations were low (Level 3-4) or indeterminable. The GRADE assessment revealed a very low level of evidence for a threshold for antipyresis.

Conclusion: There is no recommendation on which all guidelines agree, and many are inconsistent with the evidence – this is true even for recent guidelines. The threshold question is of fundamental importance and has not yet been answered. Guidelines for the most frequent intervention (antipyresis) remain problematic.

Introduction

Clinical observation has shown that fever is a physiologically controlled elevation of temperature with a strongly regulated upper limit (via protective endogenous antipyretics and inactivity of thermosensitive neurons at temperatures above 42°C). It rarely reaches 41°C and does not spiral out of control [1] as is feared by many parents and health professionals [2–4]. Divergent attitudes towards fever have led to a high level of inconsistency in approaches to its management. Many healthcare providers and parents view fever as a dangerous condition or a discomfort to be eliminated [5], despite evidence that fever is an evolutionary resource that aids in overcoming acute infections [6]. Antipyretic treatment can be harmful: in 2006, accidental paracetamol overdose caused 100 deaths in the USA alone [7]. A number of organizations have responded to this situation by developing clinical practice guidelines (CPGs) for management of fever in children with goals of guiding antipyretic treatment, responding to discrepancies between evidence and clinical practice, and diminishing irrational fear of fever and overzealous attempts at its suppression. Nevertheless, a published review addressing the quality of seven such CPGs [8] concluded that even guidelines judged as “high quality” are neither comprehensive in content nor in agreement with each other in their recommendations. Whether these conclusions apply to the full spectrum of guidelines for management of fever in children remains uncertain. Therefore, we have summarized all recommendations made by existing fever management CPGs, and assessed the level of evidence for each recommendation.

Methods

Relevant medical guideline databases were identified through a google search for ‘medical guideline databases’ and then searched using the following search terms: ((((((children[MeSH Terms]) OR (pediatric[MeSH Terms])) OR (children[Title/Abstract])) OR (pediatric[Title/Abstract])) AND (((treatment[MeSH Terms]) OR (therapy[MeSH Terms])) OR (management[Title/Abstract])) OR (intervention[Title/Abstract]))) AND (((guideline[MeSH Terms]) OR (principles[MeSH Terms])) OR (guideline[Title/Abstract])) OR (principles[Title/Abstract])) AND (((fever[MeSH Terms]) OR (pyrexia[MeSH Terms])) OR (fever[Title/Abstract]))) OR (pyrexia[Title/Abstract])). 1. A search for CPGs (defined as documents on symptomatic fever management in children, issued by governmental

organizations, pediatric associations or other healthcare groups) was conducted on the medical databases listed below, as well as websites of the above-mentioned organizations. 2. Google searches incorporating the country name in addition to the original search criteria were then carried out for each of the 195 countries in an attempt to identify any documents that had been missed by the previous methods. 3. A list of national pediatric associations was obtained from the International Pediatric Association's website (<http://ipa-world.org/society.php>) and the website of each association was searched for relevant documents using the term "fever" in the language of each country. CPGs between the dates of 1995 and September 1, 2020 in the 57 languages available on Pubmed, were included. Only the latest CPG of each series was included. Articles that did not focus on the symptomatic management of fever, or were exact copies of other guidelines, were excluded.

The following databases were included in the search: PubMed, Google Scholar, National Guideline Clearing House (<https://www.guideline.gov/>), Canadian Medical Association CPG Infobase (<https://www.cma.ca/En/Pages/clinical-practice-guidelines.aspx>), Danish Health Authority National Clinical Guidelines (<https://www.sst.dk/en/national-clinical-guidelines>), Haute Autorite de Sante (https://www.has-sante.fr/portail/jcms/fc_1249693/en/piliers), German Agency for Quality in Medicine (<http://www.leitlinien.de/nvl/>), Dutch Institute for Healthcare Improvement (<http://www.cbo.nl/>), Scottish Intercollegiate Guidelines Network (<http://www.sign.ac.uk/>), National Institute for Health and Care Excellence (<https://www.nice.org.uk/guidance>), Malaysia Ministry of Health (<http://www.moh.gov.my/english.php/pages/view/218>).

Data

We constructed a table summarizing guideline information (country, title, source, date); pharmacologic recommendations (threshold temperature for antipyretic treatment, recommended medications, posology) and non-pharmacologic recommendations (ice/cold/tepid sponge baths, hydration status, nutrition, ambient temperature, dress, covering, compresses, activity level, complementary/herbal recommendations) according to age group (S1 Table).

Quality of evidence assessment

For each recommendation, two authors conducted a search for the highest level of supporting evidence as defined by a modified version of the OCEBM Criteria (Oxford Centre for Evidence Based Medicine)[9]. Systematic reviews of randomized trials provided the highest quality evidence (level 1); systematic reviews of observational and single randomized control trials, the second level of evidence (level 2); individual prospective observational studies and systematic reviews of case reports the third (level 3); individual case reports the fourth (level 4); and mechanistic explanations the fifth (level 5). Our modifications to the OCEBM included assigning systematic reviews of prospective observational studies to Level 2 and systematic reviews of case reports to Level 3, as well as relevant non-human studies of high quality to level 5. We also rated the rigour of systematic reviews using AMSTAR criteria (“A Measurement Tool to Assess systematic Reviews”) [10] ; if the review met fewer than 7 out of the 11 AMSTAR criteria we rated the quality of evidence down one level (e.g. if a systematic review of randomized trials failed AMSTAR criteria we classified the quality of evidence as level 2 rather than level 1) [10]. Apart from one main question (see below), we did not perform a formal quality assessment of each body of evidence. We created a table categorizing and comparing the CPG statements and the highest level of evidence found in the literature in support of each statement. Two authors independently rated the quality of the evidence and resolved disagreement through discussion.

GRADE Assessment of the threshold question

We found conflicting statements and a lack of evidence regarding one fundamental category that affects almost all other recommendations. This concerns the question: “is there a temperature above which antipyresis should be attempted in acute febrile infections in children?” – in short: the threshold question. Since the NICE guidelines [11] have previously been judged to be of high quality [8], and make a recommendation to treat distress rather than body temperature, we thoroughly examined their data for evidence supporting a lack of temperature threshold and determined that the conclusion they came to was unjustified based on the evidence that they provided.

Two authors then independently attempted to address this question using the GRADE method [12]. One author used the search terms: “fever AND temperature threshold AND children AND guideline AND permissive treatment” and identified a pilot RCT trial [13] and 8 papers related to threshold that were surveys and thus deemed ineligible for inclusion in a GRADE analysis. The other author used the terms: (((“acetaminophen”[MeSH Terms] OR “acetaminophen”[All Fields]) OR (“acetaminophen”[MeSH Terms] OR “acetaminophen”[All Fields] OR “paracetamol”[All Fields]) OR antipyresis[All Fields] OR (“ibuprofen”[MeSH Terms] OR “ibuprofen”[All Fields]) OR threshold[All Fields] OR (“antipyretics”[Pharmacological Action] OR “antipyretics”[MeSH Terms] OR “antipyretics”[All Fields] OR “antipyretic”[All Fields])) AND (harm[All Fields] OR benefit[All Fields] OR outcome[All Fields] OR (“mortality”[Subheading] OR “mortality”[All Fields] OR “mortality”[MeSH Terms]) OR (“epidemiology”[Subheading] OR “epidemiology”[All Fields] OR “morbidity”[All Fields] OR “morbidity”[MeSH Terms]) OR (“immune system phenomena”[MeSH Terms] OR (“immune”[All Fields] AND “system”[All Fields] AND “phenomena”[All Fields]) OR “immune system phenomena”[All Fields] OR (“immune”[All Fields] AND “function”[All Fields]) OR “immune function”[All Fields]) OR distress[All Fields])) AND ((peak[All Fields] AND (“body temperature”[MeSH Terms] OR (“body”[All Fields] AND “temperature”[All Fields]) OR “body temperature”[All Fields])) OR (“fever”[MeSH Terms] OR “fever”[All Fields]) OR (“fever”[MeSH Terms] OR “fever”[All Fields] OR “febrile”[All Fields]) OR (“fever”[MeSH Terms] OR “fever”[All Fields] OR (“elevated”[All Fields] AND “temperature”[All Fields]) OR “elevated temperature”[All Fields])) and identified 1704 papers.

Results

Guideline selection

The search procedure identified 586 documents, of which 441 were excluded due to lack of relevance or duplication after screening titles and abstracts. The remaining records (n=145) were retrieved in full text. After examining the full text version, a further 71 documents were excluded because they were not CPGs. Finally, 74 guidelines [11, 14–86] were included: three international guidelines as well as the national guidelines for 49 countries (multiple guidelines published by different associations exist in some countries)

145 (S1 Table). Six countries follow the recommendations of another national or international guideline.
 146 Therefore, our study represents the fever management recommendations of at least 55 countries.
 147 A detailed inventory of the categories and sub-categories of recommendations revealed conflicting advice
 148 in all categories. Furthermore, only a few CPGs provided references to substantiate their recommendations.
 149 Table 1 and Figures 1-3 summarize the results; for full details, see S1 Table.
 150 **Figure 1. PRISMA Flow Diagram:** Selection of guidelines.
 151 **Figure 2. Threshold for Antipyresis:** The temperatures indicate the height of the given threshold.
 152 **Figure 3. Summary of Recommendations:** Y-axis: numbers of guidelines reporting.

Table 1. Recommendations and Evidence Level

Threshold for treating fever			
	Recommendation/ Statement	Number of guidelines reporting (69)	OCEBM Evidence Level
	No: treat distress	32	Level 5 ; physiological reasoning and clinical experience [87]
	No: treat distress + minimum temperature	12	
	Yes	22	Level 4 ; small pilot RCT that 39.5°C is the minimum temperature [13] but no direct published evidence that a threshold is necessary at all
Paracetamol			
General information	Recommendation/ Statement	Number of guidelines reporting (69)	OCEBM Evidence Level
	Recommended	69	Level 1 ; lowers temperature compared to placebo (multiple SRs) [88, 89] Level 3 ; relieves discomfort in febrile illness (down-graded because SR only included 3 studies and only 44% of children showed less discomfort compared to ibuprofen 69%); (SR) [88]
	Sole recommended antipyretic	9	No published evidence comparing ibuprofen and paracetamol shows a superior effect or safety profile of paracetamol (Review appraisal) [90]
	As the 1st line antipyretic	17	Level 1 ; review appraisal [90] SR [89]
	As 2nd line antipyretic after ibuprofen/physical methods	1	Level 2 ; RCT, meta-analysis [91]
Dose determination	Follow doctor's advice	6	Level 1 ; dose by weight and/or age; SR[89]
	Follow package instructions	4	
	Dose by age and weight	3	
	Dose by weight	8	
Dosage (mg/kg/dose)	10	2	Level 3 ; non-randomized clinical study [92]
	10-15	14	Level 1 ; SR [89]

	15	13	Level 1; SR [93]
	20	1	Level 3 against! (upgraded due to clear causality); case reports showing harm at 20 mg/kg/day over 3-4 days [94]
Dose interval	Give every 4 hours	7	No direct published evidence comparing intervals with same dose Level 5 for every six hours [93]
	Give every 4-6 hours	17	
	Give every 6 hours	6	
	Give every 6-8 hours	4	
Maximum number of doses per day	Recommendation/ Statement	Number of guidelines reporting (9)	OCEBM Evidence Level
	2 doses	1	Level 5 ; 4 doses/day, regularly every 6 hours to maintain plasma concentration; physiology [93]
	4 doses	4	
	5 doses	3	
	6 doses	1	
Maximum dosage per 24 hours	Recommendation/ Statement	Number of guidelines reporting (15)	OCEBM Evidence Level
	40 mg/kg/day	1	Level 3 for max 60 mg/kg/day; prospective study showing risks over >60 mg/kg/day [95] Level 4 for 75 mg [96]
	60 mg/kg/day	9	
	65 mg/kg/day	1	
	80 mg/kg/day	1	
	90 mg/kg/day	3	
Maximum duration of treatment	Recommendation/ Statement	Number of guidelines reporting (10)	OCEBM Evidence Level
	24 hours	1	Level 3 for 72 hours [97] No published evidence directly comparing duration of treatment
	48 hours	6	
	72 hours	3	
Ibuprofen			
General information	Recommendation/ Statement	Number of guidelines reporting (55)	OCEBM Evidence Level
	Recommended	53	Level 1 for temperature reduction [88, 91, 98, 99] Level 2 for relief of discomfort, SR (downgraded because it only included 3 studies and only 69% of children showed reduced distress) [88]
	Not recommended	2	No published evidence supports this
	As the 1st line antipyretic	0	Level 1 SR [88, 91, 98, 99]

	As 2nd line antipyretic after paracetamol	11	No published evidence shows as inferior to paracetamol [90]
Caution/avoid in:	Kawasaki disease	1	Level 5 pharmacologically sensible [100]
	Influenza	1	Level 5 (SR of animal studies [101] + mention of unpublished data [102]; review [103])
	Hemorrhagic fever	1	No direct published evidence Level 5 against! [104]
	Liver disease	3	Level 4 , several case reports summarized in review [90, 105, 106]
	Chicken pox	12	Level 3 , 5 observational studies [90, 107]
	Allergy/asthma/hypersensitivity	3	Level 4 , Retrospective [108] Level 2 against! [90] and SR [109, 110]
	Dehydration	8	Level 4 , summary of 11 case reports/retrospective [90]
	Renal insufficiency	2	Level 4 , summary of 11 case reports/retrospective [90]
	GI disease	2	Level 4 , summary of 12 case reports and retrospective studies [90]
	Bacterial infection	1	Level 4 , retrospective study, case control [111–114]
	Complex medical conditions	2	No direct published evidence
Dose determination/instructions	Recommendation/Statement	Number of guidelines reporting (32)	OCEBM Evidence Level
	Take with food	1	Level 5 against! [115]
	Follow doctor's advice	6	No direct published evidence
	Follow package instructions	4	
	Dose by weight	4	
Dosage (mg/kg/dose)	5-10 mg/kg /dose	3	Level 2 , RCT [116]
	7-10 mg/kg/dose	1	Level 2 , RCT [117]
	10mg/kg/dose	8	Level 2 , RCT [118]
	10-15mg/kg/dose	1	No published evidence
Interval between doses	Recommendation/Statement	Number of guidelines reporting (17)	OCEBM Evidence Level

	6 hours	5	No direct published evidence comparing
	6-8 hours	11	
	8 hours	1	
Maximum number of doses per day	Recommendation/ Statement	Number of guidelines reporting (10)	OCEBM Evidence Level
	2 doses	1	No direct published evidence comparing
	3 doses	3	
	4 doses	6	
Maximum dosage per 24 hours (mg/kg/day)	Recommendation/ Statement	Number of guidelines reporting (10)	OCEBM Evidence Level
	20-30	2	No direct published evidence comparing
	30	2	
	40	4	
	45	1	
	1200 mg/day	1	
Maximum duration of treatment	72 hours	3	No direct published evidence
Acetylsalicylic acid			
General	Recommendation/ Statement	Number of guidelines reporting (29)	OCEBM Evidence Level
	Not recommended <18 years	16	Level 4 , based on epidemiological association with Reyes syndrome, aspirin should not be used to treat acute febrile viral illness in children [119]
	Recommended/possible	13	
Minimum age	>5 years	1	No direct published evidence stating exactly which age aspirin is safe
	>10 years	1	
	>12 years	2	
	>14 years if they have already had varicella	1	
	>15 years	1	
	>16 years	2	
Dosage	60 mg/kg/day	1	No direct published evidence
	1g/3 times per day	1	
Avoid in	Chicken pox	2	Level 4 , case report [120]
	Hemorrhagic disorders	1	Level 5 , due to effect on platelets and bleeding diathesis [121]
Other antipyretics			
Ketoprofen	Recommended	4	Level 2 , RCT [122, 123]
	Follow doctor's advice	1	Level 2 , RCT for 0.5 mg/kg/dose [122]

	2mg/kg/day in 4 doses	3	
Diclofenac	Recommended 2nd line	1	Level 3, RCT [124, 125]
	Every 12 hours	1	No published evidence
Mefenamic acid	Recommended	3	Level 3, RCT [126]
	Not recommended	1	Level 4 [127]
	Follow doctor's advice	1	No published evidence
	6-7 mg/kg/dose max 3 times per day	2	Level 3, RCT [126]
Metamizole	Recommended	2	Level 3, RCTs downgraded [128][129]
	Not recommended	3	Level 3, Single blind clinical trial [130]
	Prescription only	1	No published evidence
	10-15 mg/kg, every 6-8 hours	1	No published evidence
Naproxen sodium	Recommended	1	Level 3, RCT [131]
	Not recommended	1	No published evidence
	220 mg every 8-12 hours (>12 years)	1	No published evidence
Alternating/combining antipyretics			
	Recommendation/ Statement	Number of guidelines reporting (39)	OCEBM Evidence Level
	Not recommended	28	Level 1, SR [132–134]
	Alternate and/or combine if necessary	8	No published evidence that makes this conclusion; Level 4 against! Retrospective analysis [135] found 4 times more likely to suffer acute kidney injury
	Insufficient evidence to make recommendation	1	Level 1, Cochrane review [136]
	Switching to other drug if 1st line drug fails	3	No published evidence showing a benefit to this
Prevention of febrile seizures			
	Recommendation/ Statement	Number of guidelines reporting (37)	OCEBM Evidence Level
	Antipyretics not recommended for prevention	26	Level 1, SR [137–139] RCT
	Evidence is inconclusive	1	No published evidence
	Recommended for prevention	10	Level 3, Prospective study [140]

Age dependent treatment recommendations			
General	Recommendation/ Statement	Number of guidelines reporting (21)	OCEBM Evidence Level
<2 months	Extend interval between paracetamol doses to 6-8 hours	1	Level 5 , review of pharmacokinetics/dynamics [141]
	No paracetamol < 2 months	2	No direct published evidence
	No paracetamol <6 weeks	1	No direct published evidence
	Only paracetamol is recommended for neonates	1	No direct published evidence
	Paracetamol not recommended for neonates	4	No direct published evidence
	Neonatal dosage 10mg/kg/dose 3-4 times per day	1	No direct published evidence
	Neonatal dosage 7.5 mg/kg/dose max 30 mg/kg/day	1	No direct published evidence
	Premature infants <32 weeks 15mg/kg/dose, 8-12 hours, 2 doses per day	1	Level 5 [141]
	32-36 weeks 15mg/kg/dose, 6-8 hours, 3 doses per day	1	No direct published evidence
	>37 weeks 15mg/kg/dose, 4-6 hours, 4 times per day	1	No direct published evidence
<4 months	Paracetamol recommended from 3 months	3	No direct published evidence
	Follow doctor's advice when child is less than 3 months	1	
	Follow doctor's advice when child is less than 4 months	1	
	Avoid ibuprofen <3 months	4	
	Maximum dose paracetamol <3 months 60mg/kg/day	1	
	Maximum dose paracetamol >3 months 80mg/kg/day	1	

<6 months	Avoid ibuprofen <6 months	11	Level 4 review of evidence [142]; can be used safely age 3-6 months, dosage 5-10 mg/kg
	Ibuprofen has more side effects in children <6 months	1	
	Ibuprofen 5mg/kg/dose	1	
	Follow doctor's advice when child is less than 6 months	1	No published evidence
	Avoid mefenamic acid if child is less than 6 months	2	
	Avoid ketoprofen if child is less than 6 months	2	
<1 year	Ibuprofen should be avoided if child is less than 1 year	1	No direct published evidence supports this; safe from 3 rd month [142]
	Diclofenac should be avoided if child is less than 1 year	1	
	Avoid compresses in children less than 1 year	1	
>10 years	Paracetamol dose is 500mg-1g every 6-8 hours, max 4g per day	1	No direct published evidence
>12 years	Nimesulide is an option	1	Level 2 , SR [143] suggests it is possible >6 months
	Nurofen is an option	1	No published evidence
	Naproxen sodium is an option	1	No published evidence
Physical methods			
Cool/ice bath	Recommendation/ Statement	Number of guidelines reporting (39)	OCEBM Evidence Level
	Not recommended	34	Level 2 (for temporary antipyretic effect but unphysiological) RCT [144]; Level 2 , RCT [144] causes discomfort
	Recommended	5	No published evidence
Alcohol rubs	Not recommended	12	Level 1 , dramatic effect case reports [145–149]
Lukewarm baths	Recommended	4	See tepid sponge baths
Physical measures should be 1st line	Recommended	1	No published evidence

	Recommendation/ Statement	Number of guidelines reporting (49)	OCEBM Evidence Level
Tepid sponging	Not recommended	16	Level 1, SR [150, 151]
	Recommended	33	No direct published evidence
Instructions for sponge baths	Water temperature 37°C and progressively cool	1	No direct published evidence; RCT showed that adding sponging to antipyretic not effective [152]
	Water temperature 27-35°C	1	
	Sponge bath 30min after taking antipyretic	4	
	Add peppermint oil to bath	1	
	Alternative in case of allergy to antipyretic	1	
	max. duration: 30 min	1	
Compresses	Number of guidelines reporting	26	No direct published evidence
	Not recommended	8	
	Recommended	18	
	Use if antipyretic fails	2	
	Use after antipyretic	2	
	Head/face	5	
	Neck	1	
	Arms	1	
	Calves	6	
	Armpits & groin	1	
	Avoid if extremities are cold	1	
	Apply for 20 min and repeat	1	
	Ice packs over large vessel areas	1	
Fluid intake			
Encourage increased fluid intake	Number of guidelines reporting	56	Level 3, SR [153] exercise care
Type of fluids	Cool drinks	2	No direct published evidence
	Water	10	
	Fruit juice	4	
	Dilute fruit juice	5	
	Breast milk	3	
	Formula	1	
	Vegetable stock	1	
	Electrolyte solution	1	
	Jello	1	

	Rice water	1	
	Coconut milk	1	
	Fizzy/soft drinks	2	
	Popsicles	3	
	Tea	3	
	Cows milk	2	
	Cordial	1	
Amount	50-80ml/kg	1	No direct published evidence
	10cc/kg/°C rise in temperature	1	
Nutrition			
Instructions	Recommendation/ Statement	Number of guidelines reporting (13)	OCEBM Evidence Level
	Normal if child doesn't want to eat; don't force	9	No direct published evidence
	Feed the child if hungry	1	
	Light, low-fat diet	2	
	Offer child's regular foods	2	
	Offer favorite food	1	
	Eat small amounts frequently	1	
Type of foods recommended	Salty soup	4	
	Fresh fruit	2	
	Popsicles	2	
	Gelatine	2	
	Low fat biscuits	1	
	Noodles	1	
	Porridge	1	
Environment			
Ambient Temperature	Recommendation/ Statement	Number of guidelines reporting (24)	OCEBM Evidence Level
	Warm room	3	No direct published evidence
	21-23°C	1	
	20-22 °C	1	
	20-21°C	1	
	Normal/child preference	4	
	Not too warm	2	
	Cool	12	
Fan/ventilated room	Recommendation/ Statement	Number of guidelines reporting (19)	No direct published evidence
	No fanning or ventilation	2	
	Fan/ventilation recommended	15	
	No drafts	1	

	Fan over liquid to increase heat loss	1	
	Fan if room is stuffy	1	
	According to comfort of child	2	
	Possible, but inconclusive research	1	
Dress of the child	Recommendation/ Statement	Number of guidelines reporting (48)	Level 5, physiological; dress appropriately for fever phase [154]
	Remove excess clothing	5	
	Dress in light weight clothing	23	
	Undress/underwear	10	
	Dress according to child’s comfort	5	
	Don't overdress	2	
	Don't underdress	2	
	Dress normally	1	
Cover /uncover	Recommendation/ Statement	Number of guidelines reporting (30)	Level 5; cover according to phase of fever [154] RCT on uncovering [155] vs. paracetamol and sponging that showed very little benefit to unwrapping
	Cover lightly	13	
	Cover if cold, uncover if hot, according to child’s comfort	11	
	Don't overbundle	2	
	Cover during phase of temperature rise and remove later	1	
	Change sheets frequently	1	
	Uncover	4	
Activity Level	Recommendation/ Statement	Number of guidelines reporting (14)	Level 3, clinical trial: bed rest not necessary) [156]
	Promote rest	7	
	Follow child's wishes	3	
	Bed rest is not necessary	4	
	Stay at home	3	
Complementary/alternative recommendations			
	Recommendation/ Statement	Number of guidelines reporting (5)	Level 3, prospective cohort study [157]; RCT [158]
	Anconitum (homeopathy)	2	
	Belladonna (homeopathy)	2	

	Ferrum phosphoricum (homeopathy)	2	
	Chamomile (homeopathy)	1	
	Mixtures (homeopathy)	1	
	Enema	1	Level 4 [159, 160] case study
	Stomach lavage	1	No direct published evidence
	Vinegar mustard rub	1	

GRADE assessment

The search identified several articles addressing the impact of fever management on disease outcome in ICU patients. However, upon closer examination these studies either included a threshold value for rescue therapy and/or specifically excluded children [161]. With the exception of two studies [162, 163] (Table 2), even the placebo arms of antipyretic RCTs operated with a threshold rescue value; and neither study reported outcomes related to temperature and morbidity/mortality. It is likely that permissive management of fever did not result in negative outcomes because this would have been reported but as the outcomes were not measured, the studies could not be included.

Table 2. GRADE Analysis: Evidence Tables

No. of Studies	Intervention	Effect	Quality	Design	Limitations	Inconsistency	Indirectness	Imprecision	Pub. Bias
Effect of antipyresis on morbidity/mortality in children with acute febrile infections									
1 Dallimore et al., 2018	Antipyresis (drug or physical)	No Tx or rescue therapy (most studies 39.5 °C)	RR 1.01 95% [CI], 0.81–1.28; <i>P</i> = 0.95	VERY LOW	SR of 13 RCT	Yes (-1) Several trials had method. weaknesses	None	Yes (-1) Population excluded children Wide CI estimates	None
1 Peters et. al., 2019	Antipyretic drug treatment	No Tx or rescue therapy (up to 39.5 °C)	Not measured as a primary outcome “rates were similar”	VERY LOW	RCT	Yes (-2) Small sample size, outcomes not quantified	None	Yes (-1) Only children on ventilation assistance were included	None

Tx = Expected treatment, RR = relative risk, CI = Confidence interval, P = p-value, °C = degree celsius, SR = systematic reviews, RCT = randomized controlled trials

Discussion

Main Findings

A comparison of worldwide fever management guidelines, revealed striking discrepancies with each other and with scientific literature on all parameters. The heterogeneity of the recommendations and the low quality of evidence on which they are based, point to a need for better data. Through summarizing and assessing the available evidence, we provide an extensive basis for the development of a consensus and evidence based, interdisciplinary fever guideline.

Temperature threshold for antipyresis: Evidence vs. clinical practice

The majority of CPGs recommend against treatment of fever itself, regardless of temperature. In the guidelines that give a threshold for antipyresis, there is little agreement about the temperature, with values ranging from 37.5°C to 40.5°C and no rationale provided. Our GRADE assessment suggests – with a very low quality of evidence – that there is no need for a threshold for antipyresis below 39.5 °C because that was the maximum threshold used in the studies [13, 161]. Whether a threshold is necessary remains unclear because there are no adequate studies. Despite the majority of guidelines recommending against giving antipyretics based on body temperature, studies of health care workers have shown that most believe that the risk of heat-related adverse outcomes is increased with temperatures above 40°C (104°F) and that more than 90% of doctors prescribe antipyretic therapy at temperatures >39°C [164, 165]. Even in the UK, a country with longstanding guidelines that recommend only treating distress, a large study of pediatric ICUs has shown that the threshold for treatment of fever is still 38°C and that 58% of care-givers asked, considered a fever of 39°C unacceptable (16).

Pharmacologic treatment: Choice of drug, dosing, adverse effects

Paracetamol is the only medication recommended by all guidelines and 17 give it preference over ibuprofen. Although high quality evidence (Level 1) has shown that they are both effective in lowering temperature, the evidence for effectiveness in distress reduction (the more relevant outcome) is lower (Level 3). There is no justification for paracetamol being the sole, or debatably, even the first-choice

antipyretic as no systematic review or RCT comparing it with ibuprofen has shown a superior effect or safety profile. 15 out of 30 RCTs comparing paracetamol and ibuprofen concluded that ibuprofen is superior in effect while the remainder found no significant difference in either effect or safety profiles [90]. This raises the question as to whether paracetamol should be relegated to second-line [91, 167] because while the safety profiles of both drugs are equivalent at therapeutic doses, the toxic level of paracetamol is reached much sooner and causes more deaths than supratherapeutic doses of ibuprofen [168][7]. Adverse effects caused by ibuprofen generally resolve, although there have been deaths due to triggering of asthma as well as long-term complications from toxic epidermal and soft tissue necrolysis [90]. Also, despite high level evidence [132–134] that combining/alternating antipyretics leads to little additional benefit in temperature control, is associated with a higher risk of supratherapeutic dosing and has not been shown to reduce discomfort, the rate of alternating antipyretics in medical practice is 67% [169]. Given that parents misdose antipyretics in almost half of cases with 15% using supratherapeutic doses [170], arriving at a consensus regarding medication choice and dose, along with methods of communicating this to parents would be a valuable contribution towards standardization of fever management. For a full discussion of dosage recommendations, see e-Supplement.

Antipyretics for prevention of febrile seizures: No evidence

Several systematic reviews and RCTs have shown that antipyretics are ineffective in preventing febrile seizures (Level 1 [137–139]). Interestingly, one trial found that antipyretics are ineffective in lowering the temperature at all during febrile episodes that are associated with febrile seizure [138]. However, a recent study concluded that rectal paracetamol administration significantly decreased the likelihood of recurrent febrile seizures during the same fever episode [140].

Nonpharmacologic measures: Fluid intake, bath, rubs and compressions

Many guidelines recommend an adequate/increased intake of fluids in order to avoid dehydration. Caution should be observed in universally recommending increased fluids as it may cause harm [153]. No direct published evidence was found regarding the optimal amount or type of fluid intake during fever. Proctoclysis is only mentioned in one guideline though the literature suggests that it could be

helpful in maintaining hydration status (Level 4), resulting in increased well-being and fewer hospitalizations [159, 160, 171–178]. Nutrition is mentioned in 25% of the guidelines with a majority in agreement that children should not be forced to eat during fever. We share this opinion, but found no studies on this.

In terms of other physical recommendations, several seemingly opinion based, contradictory approaches are mentioned: cool to warm room temperatures, ventilated to unventilated rooms, bundling to undressing the child completely, and bedrest to normal activity. A systematic review that attempted to analyze these factors [150] found that there were no studies investigating physiological interventions or environmental cooling measures as separate interventions.

Given the lack of evidence, one may appeal to knowledge of the fever process to determine that appropriate use of physical measures depends on the fever phase: As the fever is rising, the child should be kept warm or even actively warmed – thus reducing the energy needed to develop fever and thereby discomfort. Once the child is warm all the way to its feet and starts sweating, layers of sheets and clothing can be carefully removed (level 5 [154]).

Despite high level evidence (level 1) that tepid sponging increases discomfort and should be avoided [150, 151], 61% of guidelines are still in favor of its use. Recommendations about compresses show a similar distribution (63% in favor) though fewer guidelines address the topic and little directly applicable research is available. The decrease in temperature that results from external cooling is of short duration. A mismatch between the hypothalamic set point and skin temperature leads to peripheral vasoconstriction and metabolic heat production, which results in shivering and increased discomfort of the child. The initial small reduction in body temperature is not worth the potential discomfort and the use of these methods indicates a continued focus on the reduction of body temperature rather than distress.

Complementary recommendations

Recommendations on complementary treatments only appear in three guidelines, despite their widespread use by parents and health professionals. The evidence for the proposed treatments is low

(Level 4) – perhaps partially because most forms of alternative medicine do not advocate fever suppression as a treatment goal. With regard to well-being, the scientific literature suggests greater or equal efficacy and satisfaction compared with conventional treatments, with high safety and tolerability [157, 158, 179–181].

Other potential issues not yet included in the published guidelines

Digital media: None of the guidelines mention screen exposure. Most countries are beginning to formulate recommendations on child screen exposure [182]. We point to the need for recommendations on screen use in illness.

Parental care by interaction and empathy and relationship: None of the guidelines mention the quality of parental care during illness, which may be the most important factor for both immediate well-being and long-term health [183]. Finding ways to reduce fever phobia by education or counseling intervention may contribute to relational and empathetic fever management and facilitate a significant reduction of distress [184, 185].

Limitations and Strengths

Only 74 guidelines were retrieved which, considering the high frequency of fever, is fewer than expected. We cannot exclude that other documents exist as some may not be online and our attempts to contact these countries' pediatric societies per email did not yield any additional documents. Out of a responsibility for resource investment, we refrained from duplicate assessment of guideline eligibility, risk of bias for the individual intervention and duplicate data extraction (except for the GRADE assessment, which was duplicate), judging that minor changes would have no effect on the overall guideline assessment results. Due to a lack of information regarding the developmental procedure of most guidelines, an overall assessment of quality (using AGREE II) was not feasible. Therefore, we chose to examine the supporting evidence for each of the recommendations using the OCEBM criteria [9] and discuss the results based on the highest level of evidence. This is a unique strength of this review.

Conclusion

A comparison of worldwide fever management guidelines, revealed some uniform themes and recommendations supported by a high level of evidence, but also striking discrepancies and a low level of evidence supporting most recommendations. So far, we can conclude that some recommendations should be part of all guidelines:

- Parents and carers should be educated about the benefits of fever, and how to recognize and act on othersigns of danger and judge the condition rather than fever alone.
- In an otherwise healthy child with an acute febrile infection, treatment should focus on reduction of distress rather than temperature (Level 5). The social and physical environment should be optimized before considering use of antipyretic medications (Level 5).
- Antipyretics should not be combined (Level 1), or routinely alternated (Level 1), and be used, if at all, only as long as the child appears distressed (Level 5).
- Antipyretics should not be given with the intention of preventing febrile seizures (Level 1)
- External cooling may increase discomfort and metabolic strain (Level 1).

None of the CPGs include statements about the potential benefits of fever (level 1). Studies are needed to assess whether educating parents and carers (i.e. about the side effects of antipyretics, the positive immunological effects of fever and how to recognize signs of danger) influences outcomes. The question as to whether or not there should be a threshold for initiating antipyresis must be met with solid evidence.

References

1. DuBOIS EF (1949) Why are fever temperatures over 106 degrees F. rare? Am J Med Sci 217:361–368
2. Karwowska A, Nijssen-Jordan C, Johnson D, Davies HD (2002) Parental and health care provider understanding of childhood fever: a Canadian perspective. CJEM 4:394–400
3. Crocetti M, Moghbeli N, Serwint J (2001) Fever phobia revisited: have parental misconceptions about fever changed in 20 years? Pediatrics 107:1241–1246

- 294 4. Elkon-Tamir E, Rimon A, Scolnik D, Glatstein M (2017) Fever Phobia as a Reason for
295 Pediatric Emergency Department Visits: Does the Primary Care Physician Make a
296 Difference? Rambam Maimonides Med J. <https://doi.org/10.5041/RMMJ.10282>
- 297 5. Purssell E, Collin J (2016) Fever phobia: The impact of time and mortality--a
298 systematic review and meta-analysis. *Int J Nurs Stud* 56:81–89
- 299 6. Duff GW (1986) Is fever beneficial to the host: a clinical perspective. *Yale J Biol Med*
300 59:125–130
- 301 7. Nourjah P, Ahmad SR, Karwoski C, Willy M (2006) Estimates of acetaminophen
302 (Paracetamol)-associated overdoses in the United States. *Pharmacoepidemiol Drug Saf*
303 15:398–405
- 304 8. Chiappini E, Bortone B, Galli L, de Martino M (2017) Guidelines for the symptomatic
305 management of fever in children: systematic review of the literature and quality
306 appraisal with AGREE II. *BMJ Open* 7:e015404
- 307 9. OCEBM Levels of Evidence Working Group* (2016) The Oxford Levels of Evidence
308 2. In: Oxford Centre for Evidence-Based Medicine.
309 <https://www.cebm.net/index.aspx?o=5653>. Accessed 13 Sep 2018
- 310 10. Shea BJ, Reeves BC, Wells G, et al (2017) AMSTAR 2: a critical appraisal tool for
311 systematic reviews that include randomised or non-randomised studies of healthcare
312 interventions, or both. *BMJ* 358:j4008
- 313 11. National Institute for Health and Care Excellence (NICE) (2017) Fever in under 5s:
314 assessment and initial management | Guidance and guidelines | NICE.
315 <https://www.nice.org.uk/guidance/cg160>. Accessed 23 May 2018
- 316 12. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P,
317 Schünemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence
318 and strength of recommendations. *BMJ* 336:924–926
- 319 13. Peters MJ, Woolfall K, Khan I, et al (2019) Permissive versus restrictive temperature
320 thresholds in critically ill children with fever and infection: a multicentre randomized
321 clinical pilot trial. *Crit Care* 23:69
- 322 14. 아기 열 날때 #소아열원인 #소아해열제 #야간진료 소아과. In: 네이버 블로그 | 연
323 세곰돌이소아과. <https://blog.naver.com/gomdori4585/221229492288>. Accessed 24
324 Sep 2020
- 325 15. Ministry of Public Health, General Directorate of Pharmaceutical Affairs (2013)
326 National Standard Treatment Guidelines for the Primary Level.
- 327 16. L'association des pédiatres libéraux d'Alger (APLA) Fièvre de l'enfant : que faire? In:
328 apla. <http://www.apla-dz.org/conseils-aux-parents/maladies-infantiles/votre-enfant-a-de-la-fievre/>. Accessed 23 May 2018
329

- 330 17. SAP Argentine Society of Pediatrics | News | Fever. <http://www.sap.org.ar/>. Accessed
331 24 Sep 2020
- 332 18. Ի՞նչ է ցուցված և ի՞նչ է արգելվում անել, երբ փոքրիկը ջերմում է.
- 333 19. NSW Department of Health (2010) Children and Infants with Fever - Acute
334 Management.
- 335 20. Fever Without Source - Kids Health WA (PMH ED Guidelines). Kids Health WA
336 (PMH ED Guidelines)
- 337 21. South Australian Child Health Clinical Network (2013) Management of Fever without
338 Focus in Children (excluding neonates), Clinical Guideline.
- 339 22. Clinical Practice Guidelines : Febrile child.
340 https://www.rch.org.au/clinicalguide/guideline_index/Febrile_child/. Accessed 24 Sep
341 2020
- 342 23. Joana Briggs Institute (2004) Management of the Child with Fever.
- 343 24. Österreichische Gesellschaft für Kinder- und Jugendheilkunde Fieber und Schmerzen:
344 Was tun?
- 345 25. XI. LA FIEVRE CHEZ L'ENFANT. [http://www.pediatric.be/fr/xi-la-fievre-chez-](http://www.pediatric.be/fr/xi-la-fievre-chez-l_enfant/251/2)
346 [l_enfant/251/2](http://www.pediatric.be/fr/xi-la-fievre-chez-l_enfant/251/2). Accessed 23 May 2018
- 347 26. Arteaga Bonilla R (2011) Fiebre y el uso de antipiréticos en niños. Revista de la
348 Sociedad Boliviana de Pediatría 50:27–29
- 349 27. Febre: Cuidado com a Febrefobia. In: SBP. [https://www.sbp.com.br/especiais/pediatrica-](https://www.sbp.com.br/especiais/pediatrica-para-familias/cuidados-com-a-saude/febre-cuidado-com-a-febrefobia/)
350 [para-familias/cuidados-com-a-saude/febre-cuidado-com-a-febrefobia/](https://www.sbp.com.br/especiais/pediatrica-para-familias/cuidados-com-a-saude/febre-cuidado-com-a-febrefobia/). Accessed 24 Sep
351 2020
- 352 28. The College of Family Physicians Canada (2011) Fever in Infants and Children.
353 <http://www.cfpc.ca/ProjectAssets/Templates/Resource.aspx?id=3596>. Accessed 23
354 May 2018
- 355 29. What you need to know: fever. 2
- 356 30. Government of Manitoba (2006) Healthy Child, Caring for a Child with Fever.
- 357 31. Canada Pharmacist's Association (2010) Fever.
- 358 32. Canadian Pediatric Society (2015) Fever and temperature taking - Caring for Kids.
359 https://www.caringforkids.cps.ca/handouts/fever_and_temperature_taking. Accessed 23
360 May 2018
- 361 33. SOCHIFE - Soc. Chilena de Pediatría (2013) Fiebre : Tratamiento Ambulatorio.
362 http://www.sochipe.cl/v3/presenta_dos.php?id=610. Accessed 23 May 2018
- 363 34. Colombian Society of Pediatrics | SCP Colombian Society of Pediatrics.

- 364 35. support (2018) Fiebre en el niño. ACOPE C.R.
- 365 36. Actuación enfermera ante un cuadro febril en niños. [https://www.revista-](https://www.revista-portalesmedicos.com/revista-medica/actuacion-enfermera-cuadro-febril/)
366 [portalesmedicos.com/revista-medica/actuacion-enfermera-cuadro-febril/](https://www.revista-portalesmedicos.com/revista-medica/actuacion-enfermera-cuadro-febril/). Accessed 24
367 Sep 2020
- 368 37. Πυρετός και η φοβία του πυρετού | Παιδιατρική Εταιρεία Κύπρου.
369 <https://www.child.org.cy/phobia-of-fever/>. Accessed 24 Sep 2020
- 370 38. (2008) When the child has a fever. Drug and Therapeutics Bulletin 46:17–21
- 371 39. Asociación de Pediatría de El Salvador (2015) LO QUE DEBE SABER SOBRE LA
372 FIEBRE DE SU HIJO. ASOPEDES
- 373 40. Haute Autorite de Sante (2016) Prise en charge de la fièvre chez l’enfant.
- 374 41. Agence française de sécurité sanitaire des produits de santé (Afssaps) Mise au Point
375 Sur la Prise en Charge de la Fiebre Chez l’Enfant.
- 376 42. Société Française de Pédiatrie (2004) Prise en Charge Symptomatique de la Fièvre du
377 Jeune Enfant. [http://www.sfpediatricie.com/recommandation/prise-en-charge-](http://www.sfpediatricie.com/recommandation/prise-en-charge-symptomatique-de-la-fi%C3%A8vre-du-jeune-enfant)
378 [symptomatique-de-la-fi%C3%A8vre-du-jeune-enfant](http://www.sfpediatricie.com/recommandation/prise-en-charge-symptomatique-de-la-fi%C3%A8vre-du-jeune-enfant). Accessed 23 May 2018
- 379 43. Der Berufsverband der Kinder- und Jugendärzte Fieber » Sofortmaßnahmen » Erste
380 Hilfe » Kinderaerzte-im-Netz. [https://www.kinderaerzte-im-netz.de/erste-](https://www.kinderaerzte-im-netz.de/erste-hilfe/sofortmassnahmen/fieber)
381 [hilfe/sofortmassnahmen/fieber](https://www.kinderaerzte-im-netz.de/erste-hilfe/sofortmassnahmen/fieber). Accessed 23 May 2018
- 382 44. Fieber bei Kindern Patientenleitlinie [www.Patientenleitlinien.de] Fieber im
383 Kindesalter.
384 http://www.patientenleitlinien.de/Fieber_Kindesalter/fieber_kindesalter.html. Accessed
385 23 May 2018
- 386 45. Niehues T (2013) The febrile child: diagnosis and treatment. Dtsch Arztebl Int
387 110:764–773; quiz 774
- 388 46. Elterninfo Fieber. In: Deutsche Gesellschaft für Kinder- und Jugendmedizin.
389 <https://www.dgkj.de/eltern/dgkj-elterninformationen/elterninfo-fieber>. Accessed 24 Sep
390 2020
- 391 47. Ministry of Health, Republic of Ghana (2010) Standard Treatment Guidelines: - Ch 19
392 Fever.
- 393 48. Indian Academy of Pediatrics (IAP) | Search. <https://iapindia.org/search.php>. Accessed
394 24 Sep 2020
- 395 49. Jehangir Apollo hospital (2013) Fever in children.
- 396 50. Penanganan Demam pada Anak. In: IDAI.
397 <https://www.idai.or.id/artikel/klinik/keluhan-anak/penanganan-demam-pada-anak>.
398 Accessed 24 Sep 2020

- 399 51. Irish College of General Practitioners (2013) Antipyretic Prescribing 2013.
400 [https://www.icgp.ie/go/library/catalogue/item/6686EC55-D046-1DCB-](https://www.icgp.ie/go/library/catalogue/item/6686EC55-D046-1DCB-B9ED227FA2C07DA6)
401 [B9ED227FA2C07DA6](https://www.icgp.ie/go/library/catalogue/item/6686EC55-D046-1DCB-B9ED227FA2C07DA6). Accessed 23 May 2018
- 402 52. Chiappini E, Venturini E, Remaschi G, et al (2017) 2016 Update of the Italian Pediatric
403 Society Guidelines for Management of Fever in Children. J Pediatr 180:177-183.e1
- 404 53. Kodomo QQ Kids Emergency(ONLINE-QQ) - Go to the hospital by car/taxi.
405 <http://kodomo-qq.jp/en/?pname=hatsunetsu%2Fr2>. Accessed 24 Sep 2020
- 406 54. Google Translate.
407 <https://translate.google.com/translate?hl=en&sl=ar&tl=en&u=https%3A%2F%2Fjps.org>
408 [g.jo%2F%D8%A7%D9%84%D8%AD%D9%85%D9%89-%D8%A7%D9%88-](https://translate.google.com/translate?hl=en&sl=ar&tl=en&u=https%3A%2F%2Fjps.org)
409 [%D8%A7%D8%B1%D8%AA%D9%81%D8%A7%D8%B9-](https://translate.google.com/translate?hl=en&sl=ar&tl=en&u=https%3A%2F%2Fjps.org)
410 [%D8%A7%D9%84%D8%AD%D8%B1%D8%A7%D8%B1%D8%A9-](https://translate.google.com/translate?hl=en&sl=ar&tl=en&u=https%3A%2F%2Fjps.org)
411 [%D8%B9%D9%86%D8%AF-](https://translate.google.com/translate?hl=en&sl=ar&tl=en&u=https%3A%2F%2Fjps.org)
412 [%D8%A7%D9%84%D8%A3%D8%B7%D9%81%D8%A7%D9%84%2F&prev=search](https://translate.google.com/translate?hl=en&sl=ar&tl=en&u=https%3A%2F%2Fjps.org)
413 [h](https://translate.google.com/translate?hl=en&sl=ar&tl=en&u=https%3A%2F%2Fjps.org). Accessed 24 Sep 2020
- 414 55. Clinical Guidelines for Diagnosis and Treatment of Common Conditions in Kenya. 356
- 415 56. Al Salam Hospital Fever and Its Treatment. [http://www.sih-](http://www.sih-kw.com/Fever_En.cms?ActiveID=1132)
416 [kw.com/Fever_En.cms?ActiveID=1132](http://www.sih-kw.com/Fever_En.cms?ActiveID=1132). Accessed 23 May 2018
- 417 57. Ministère-Direction de la Santé (2005) Fièvre.
418 <http://www.sante.public.lu/fr/maladies/zone-corps/sang/fievre/index.html>. Accessed 23
419 May 2018
- 420 58. La fièvre chez les enfants | Kannerklinik. [https://kannerklinik.chl.lu/fr/dossier/la-fievre-](https://kannerklinik.chl.lu/fr/dossier/la-fievre-chez-les-enfants)
421 [chez-les-enfants](https://kannerklinik.chl.lu/fr/dossier/la-fievre-chez-les-enfants). Accessed 24 Sep 2020
- 422 59. Dutch College of General Practitioners (2016) Children with Fever (Page 25).
- 423 60. NVK - Document. [https://www.nvk.nl/themas/kwaliteit/overige-](https://www.nvk.nl/themas/kwaliteit/overige-kennisdocumenten/document?documentregistratieid=8257539)
424 [kennisdocumenten/document?documentregistratieid=8257539](https://www.nvk.nl/themas/kwaliteit/overige-kennisdocumenten/document?documentregistratieid=8257539). Accessed 24 Sep 2020
- 425 61. Starship Children's Hospital of New Zealand (2009) Fever Investigation and
426 Management. [https://www.starship.org.nz/for-health-professionals/starship-clinical-](https://www.starship.org.nz/for-health-professionals/starship-clinical-guidelines/f/fever-investigation-and-management/)
427 [guidelines/f/fever-investigation-and-management/](https://www.starship.org.nz/for-health-professionals/starship-clinical-guidelines/f/fever-investigation-and-management/). Accessed 23 May 2018
- 428 62. Fever in children. In: Ministry of Health NZ. [https://www.health.govt.nz/your-](https://www.health.govt.nz/your-health/conditions-and-treatments/diseases-and-illnesses/fever/fever-children)
429 [health/conditions-and-treatments/diseases-and-illnesses/fever/fever-children](https://www.health.govt.nz/your-health/conditions-and-treatments/diseases-and-illnesses/fever/fever-children). Accessed
430 24 Sep 2020
- 431 63. Den norske legeforening. <https://www.legeforeningen.no/>. Accessed 24 Sep 2020
- 432 64. PNG PAEDIATRIC SOCIETY (2016) Standard Treatment for Common Illnesses of
433 Children in Papua New Guinea (Page 61).

- 434 65. Febra izolata. In: Issuu. https://issuu.com/protocoale_pediatrie/docs/45_febra_izolata.
435 Accessed 24 Sep 2020
- 436 66. Союз педиатров России. In: Союз педиатров России. [https://www.pediatr-](https://www.pediatr-russia.ru/parents_information/soveti-roditelyam/likhoradka.php)
437 [russia.ru/parents_information/soveti-roditelyam/likhoradka.php](https://www.pediatr-russia.ru/parents_information/soveti-roditelyam/likhoradka.php). Accessed 24 Sep 2020
- 438 67. Fever: What is it, medication, other measures and when to consult a doctor. | KKH.
439 <https://www.kkh.com.sg/patient-care/conditions-treatments/fever-childhood-illnesses>.
440 Accessed 24 Sep 2020
- 441 68. Green R, Jeena P, Kotze S, Lewis H, Webb D, Wells M, Department of Paediatrics and
442 Child Health, University of Pretoria, South Africa, Department of Paediatrics and Child
443 Health, University of KwaZulu-Natal, Durban, South Africa (2013) Management of
444 acute fever in children: guideline for community healthcare providers and pharmacists.
445 S Afr Med J 103:948–954
- 446 69. Fiebre: ¿qué hacer cuando el niño tiene fiebre? | EnFamilia.
447 <https://enfamilia.aeped.es/temas-salud/que-hacer-cuando-nino-tiene-fiebre>. Accessed
448 24 Sep 2020
- 449 70. 2019 Standard Treatment Protocols - PAEDIATRICS. 1
- 450 71. MINISTRY OF HEALTH GOVERNMENT OF SOUTHERN SUDAN (2006)
451 Prevention & Treatment Guidelines for Primary Healthcare Centers and Hospitals.
- 452 72. 1177 Vårdguiden Fever in children/Feber hos barn – engelska - sjukdomar,
453 undersökningar, hitta vård, e-tjänster. [https://www.1177.se/Other-](https://www.1177.se/Other-languages/Engelska/Barn/Feber--vad-kan-man-gora-sjalv/)
454 [languages/Engelska/Barn/Feber--vad-kan-man-gora-sjalv/](https://www.1177.se/Other-languages/Engelska/Barn/Feber--vad-kan-man-gora-sjalv/). Accessed 23 May 2018
- 455 73. Swiss Pediatrics Association (1995) When children are ill: some advice for parents.
- 456 74. Ministry of Health and Social Welfare (2013) Standard Treatment Guidelines and
457 Essential Medicines List.
- 458 75. Ministry of Health Tuvalu (2010) Standard Treatment Guidelines.
- 459 76. Association of Ukrainian Pediatricians Fever and Hyperperexia In Children.
- 460 77. Mayo Clinic (2015) Fever: First aid. [https://www.mayoclinic.org/first-aid/first-aid-](https://www.mayoclinic.org/first-aid/first-aid-fever/basics/ART-20056685?p=1)
461 [fever/basics/ART-20056685?p=1](https://www.mayoclinic.org/first-aid/first-aid-fever/basics/ART-20056685?p=1). Accessed 23 May 2018
- 462 78. 7. American Academy of Pediatrics (2016) Fever. In: HealthyChildren.org.
463 [http://www.healthychildren.org/English/health-](http://www.healthychildren.org/English/health-issues/conditions/fever/Pages/default.aspx)
464 [issues/conditions/fever/Pages/default.aspx](http://www.healthychildren.org/English/health-issues/conditions/fever/Pages/default.aspx). Accessed 23 May 2018
- 465 79. UpToDate (2017) Fever in children (Beyond the Basics).
- 466 80. PubMed Health (2016) Fever in children: How can you reduce a fever?

- 467 81. Sullivan J E (2011) Fever and Antipyretic Use in Children | From the American
468 Academy of Pediatrics | Pediatrics.
469 <http://pediatrics.aappublications.org/content/127/3/580>. Accessed 23 May 2018
- 470 82. Fever in Infants and Children - Pediatrics. In: MSD Manual Professional Edition.
471 [https://www.msmanuals.com/professional/pediatrics/symptoms-in-infants-and-](https://www.msmanuals.com/professional/pediatrics/symptoms-in-infants-and-children/fever-in-infants-and-children)
472 [children/fever-in-infants-and-children](https://www.msmanuals.com/professional/pediatrics/symptoms-in-infants-and-children/fever-in-infants-and-children). Accessed 24 Sep 2020
- 473 83. SVPP. <http://www.svpedia.org/>. Accessed 24 Sep 2020
- 474 84. Medecins Sans Frontieres (2016) Clinical Guidelines: Diagnosis and Treatment
475 Manual.
- 476 85. WHO/Unicef (2007) Handbook IMCI: Integrated management of childhood illness.
- 477 86. World Health Organization (2013) WHO pocketbook of hospital care for children:
478 guidelines for the management of common childhood illness.
- 479 87. Mackowiak PA, Boulant JA (1996) Fever's Glass Ceiling. *Clinical Infectious Diseases*
480 22:525–536
- 481 88. Narayan K, Cooper S, Morphet J, Innes K (2017) Effectiveness of paracetamol versus
482 ibuprofen administration in febrile children: A systematic literature review:
483 Antipyretics in paediatric fever. *Journal of Paediatrics and Child Health* 53:800–807
- 484 89. Temple AR, Temple BR, Kuffner EK (2013) Dosing and antipyretic efficacy of oral
485 acetaminophen in children. *Clin Ther* 35:1361-1375.e1–45
- 486 90. de Martino M, Chiarugi A, Boner A, Montini G, de' Angelis GL (2017) Working
487 Towards an Appropriate Use of Ibuprofen in Children: An Evidence-Based Appraisal.
488 *Drugs* 77:1295–1311
- 489 91. Perrott DA, Piira T, Goodenough B, Champion GD (2004) Efficacy and safety of
490 acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis. *Arch*
491 *Pediatr Adolesc Med* 158:521–526
- 492 92. George M, Phelps MA, Kitzmiller JP (2012) Acetaminophen pediatric dose selection:
493 caregiver satisfaction regarding the antipyretic efficacy of acetaminophen in children.
494 *Clin Pediatr (Phila)* 51:1030–1031
- 495 93. de Martino M, Chiarugi A (2015) Recent Advances in Pediatric Use of Oral
496 Paracetamol in Fever and Pain Management. *Pain Ther* 4:149–168
- 497 94. Shahroor S, Shvil Y, Ohali M, Granot E (2000) [Acetaminophen toxicity in children as
498 a “therapeutic misadventure”]. *Harefuah* 138:654–657, 710
- 499 95. Kozer E, Barr J, Bulkowstein M, Avgil M, Greenberg R, Matias A, Petrov I,
500 Berkovitch M (2002) A prospective study of multiple supratherapeutic acetaminophen
501 doses in febrile children. *Vet Hum Toxicol* 44:106–109

- 502 96. Heard K, Bui A, Mlynarchek SL, Green JL, Bond GR, Clark RF, Kozer E, Koff RS,
503 Dart RC (2014) Toxicity from repeated doses of acetaminophen in children: assessment
504 of causality and dose in reported cases. *Am J Ther* 21:174–183
- 505 97. Temple AR, Zimmerman B, Gelotte C, Kuffner EK (2017) Comparison of the Efficacy
506 and Safety of 2 Acetaminophen Dosing Regimens in Febrile Infants and Children: A
507 Report on 3 Legacy Studies. *J Pediatr Pharmacol Ther* 22:22–32
- 508 98. Southey ER, Soares-Weiser K, Kleijnen J (2009) Systematic review and meta-analysis
509 of the clinical safety and tolerability of ibuprofen compared with paracetamol in
510 paediatric pain and fever. *Curr Med Res Opin* 25:2207–2222
- 511 99. Purssell E (2002) Treating fever in children: paracetamol or ibuprofen? *Br J*
512 *Community Nurs* 7:316–320
- 513 100. Es aconsejable evitar el ibuprofeno en la enfermedad de Kawasaki? Is it advisable to
514 avoid ibuprofen in Kawasaki disease?
- 515 101. Eysers S, Weatherall M, Shirtcliffe P, Perrin K, Beasley R (2010) The effect on
516 mortality of antipyretics in the treatment of influenza infection: systematic review and
517 meta-analysis. *Journal of the Royal Society of Medicine* 103:403–411
- 518 102. Plaisance KI, Mackowiak PA (2000) Antipyretic therapy: physiologic rationale,
519 diagnostic implications, and clinical consequences. *Arch Intern Med* 160:449–456
- 520 103. Eysers S, Jefferies S, Shirtcliffe P, Perrin K, Beasley R (2011) Antipyretic therapy for
521 influenza infection—benefit or harm? In: [https://www.nzma.org.nz/journal/read-the-](https://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2011/vol-124-no-1338/letter-eyers)
522 [journal/all-issues/2010-2019/2011/vol-124-no-1338/letter-eyers](https://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2011/vol-124-no-1338/letter-eyers).
- 523 104. Kellstein D, Fernandes L (2019) Symptomatic treatment of dengue: should the NSAID
524 contraindication be reconsidered? *Postgrad Med* 131:109–116
- 525 105. Zoubek ME, Lucena MI, Andrade RJ, Stephens C (2020) Systematic review:
526 ibuprofen-induced liver injury. *Aliment Pharmacol Ther* 51:603–611
- 527 106. Shen X, Huang Y, Guo H, Peng H, Yao S, Zhou M, Liu H, Lin H-C, Zhou P (2020)
528 Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with
529 patent ductus arteriosus. *Clin Res Hepatol Gastroenterol*.
530 <https://doi.org/10.1016/j.clinre.2020.06.019>
- 531 107. Mikaeloff Y, Kezouh A, Suissa S (2008) Nonsteroidal anti-inflammatory drug use and
532 the risk of severe skin and soft tissue complications in patients with varicella or zoster
533 disease. *Br J Clin Pharmacol* 65:203–209
- 534 108. Fu L-S, Lin C-C, Wei C-Y, Lin C-H, Huang Y-C (2019) Risk of acute exacerbation
535 between acetaminophen and ibuprofen in children with asthma. *PeerJ* 7:e6760
- 536 109. Kanabar D, Dale S, Rawat M (2007) A review of ibuprofen and acetaminophen use in
537 febrile children and the occurrence of asthma-related symptoms. *Clin Ther* 29:2716–
538 2723

- 539 110. Sherbash M, Furuya-Kanamori L, Nader JD, Thalib L (2020) Risk of wheezing and
540 asthma exacerbation in children treated with paracetamol versus ibuprofen: a
541 systematic review and meta-analysis of randomised controlled trials. *BMC Pulm Med*
542 20:72
- 543 111. François P, Desrumaux A, Cans C, Pin I, Pavese P, Labarère J (2010) Prevalence and
544 risk factors of suppurative complications in children with pneumonia: Suppurative
545 complications of pneumonia. *Acta Paediatrica* 99:861–866
- 546 112. Elemraid MA, Thomas MF, Blain AP, Rushton SP, Spencer DA, Gennery AR, Clark
547 JE, North East of England Pediatric Respiratory Infection Study Group Newcastle upon
548 Tyne, UK (2015) Risk factors for the development of pleural empyema in children.
549 *Pediatr Pulmonol* 50:721–726
- 550 113. Voiriot G, Dury S, Parrot A, Mayaud C, Fartoukh M (2011) Nonsteroidal
551 Antiinflammatory Drugs May Affect the Presentation and Course of Community-
552 Acquired Pneumonia. *CHEST* 139:387–394
- 553 114. Le Bourgeois M, Ferroni A, Leruez-Ville M, et al (2016) Nonsteroidal Anti-
554 Inflammatory Drug without Antibiotics for Acute Viral Infection Increases the
555 Empyema Risk in Children: A Matched Case-Control Study. *J Pediatr* 175:47-53.e3
- 556 115. Rainsford KD, Bjarnason I (2012) NSAIDs: take with food or after fasting? *Journal of*
557 *Pharmacy and Pharmacology* 64:465–469
- 558 116. Marriott SC, Stephenson TJ, Hull D, Pownall R, Smith CM, Butler A (1991) A dose
559 ranging study of ibuprofen suspension as an antipyretic. *Arch Dis Child* 66:1037–1042
- 560 117. Autret-Leca E (2003) A general overview of the use of ibuprofen in paediatrics. *Int J*
561 *Clin Pract Suppl* 9–12
- 562 118. Walson PD, Galletta G, Chomilo F, Braden NJ, Sawyer LA, Scheinbaum ML (1992)
563 Comparison of Multidose Ibuprofen and Acetaminophen Therapy in Febrile Children.
564 *Am J Dis Child* 146:626–632
- 565 119. Diseases C on I, Fulginiti VA, Brunell PA, Cherry JD, Ector WL, Gershon AA, Gotoff
566 SP, Hughes WT, Mortimer EA, Peter G (1982) Aspirin and Reye Syndrome. *Pediatrics*
567 69:810–812
- 568 120. Çaksen H, Güler E, Alper M, Üstünbaş HB (2001) A Fatal Case of Reye Syndrome
569 after Varicella and Ingestion of Aspirin. *The Journal of Dermatology* 28:286–287
- 570 121. Moroz LA (1977) Increased blood fibrinolytic activity after aspirin ingestion. *N Engl J*
571 *Med* 296:525–529
- 572 122. Kokki H, Kokki M (2010) Dose-finding studies of ketoprofen in the management of
573 fever in children: report on two randomized, single-blind, comparator-controlled,
574 single-dose, multicentre, phase II studies. *Clin Drug Investig* 30:251–258

- 575 123. Kokki H, Kokki M (2010) Ketoprofen versus paracetamol (acetaminophen) or
576 ibuprofen in the management of fever: results of two randomized, double-blind, double-
577 dummy, parallel-group, repeated-dose, multicentre, phase III studies in children. Clin
578 Drug Investig 30:375–386
- 579 124. Polman HA, Huijbers WA, Augusteyn R (1981) The use of diclofenac sodium
580 (Voltaren) suppositories as an antipyretic in children with fever due to acute infections:
581 a double-blind, between-patient, placebo-controlled study. J Int Med Res 9:343–348
- 582 125. Sharif MR, Haji Rezaei M, Aalinezhad M, Sarami G, Rangraz M (2016) Rectal
583 Diclofenac Versus Rectal Paracetamol: Comparison of Antipyretic Effectiveness in
584 Children. Iran Red Crescent Med J 18:e27932
- 585 126. Khubchandani RP, Ghatikar KN, Keny S, Usgaonkar NG (1995) Choice of antipyretic
586 in children. J Assoc Physicians India 43:614–616
- 587 127. Kamour A, Crichton S, Cooper G, Lupton DJ, Eddleston M, Vale JA, Thompson JP,
588 Thomas SHL (2017) Central nervous system toxicity of mefenamic acid overdose
589 compared with other NSAIDs: an analysis of cases reported to the United Kingdom
590 National Poisons Information Service. Br J Clin Pharmacol 83:855–862
- 591 128. Prado J, Daza R, Chumbes O, Loayza I, Huicho L (2006) Antipyretic efficacy and
592 tolerability of oral ibuprofen, oral dipyron and intramuscular dipyron in children: a
593 randomized controlled trial. Sao Paulo Med J 124:135–140
- 594 129. Wong A, Sibbald A, Ferrero F, et al (2001) Antipyretic effects of dipyron versus
595 ibuprofen versus acetaminophen in children: results of a multinational, randomized,
596 modified double-blind study. Clin Pediatr (Phila) 40:313–324
- 597 130. Giovannini M, Longhi R, Besana R, Michos N, Sarchi C (1986) Clinical experience
598 and results of treatment with suprofen in pediatrics. 5th communication: a single-blind
599 study on antipyretic effect and tolerability of suprofen syrup versus metamizole drops
600 in pediatric patients. Arzneimittelforschung 36:959–964
- 601 131. Cashman TM, Starns RJ, Johnson J, Oren J (1979) Comparative effects of naproxen
602 and aspirin on fever in children. J Pediatr 95:626–629
- 603 132. Purssell E (2011) Systematic review of studies comparing combined treatment with
604 paracetamol and ibuprofen, with either drug alone. Arch Dis Child 96:1175–1179
- 605 133. Pereira GL, Dagostini JMC, Pizzol T da SD (2012) Alternating antipyretics in the
606 treatment of fever in children: a systematic review of randomized clinical trials. J
607 Pediatr (Rio J) 88:289–296
- 608 134. Trippella G, Ciarcià M, de Martino M, Chiappini E (2019) Prescribing Controversies:
609 An Updated Review and Meta-Analysis on Combined/Alternating Use of Ibuprofen
610 and Paracetamol in Febrile Children. Front Pediatr.
611 <https://doi.org/10.3389/fped.2019.00217>

- 612 135. Yue Z, Jiang P, Sun H, Wu J (2014) Association between an excess risk of acute
613 kidney injury and concomitant use of ibuprofen and acetaminophen in children,
614 retrospective analysis of a spontaneous reporting system. *Eur J Clin Pharmacol* 70:479–
615 482
- 616 136. Wong T, Stang AS, Ganshorn H, Hartling L, Maconochie IK, Thomsen AM, Johnson
617 DW (2014) Cochrane in context: Combined and alternating paracetamol and ibuprofen
618 therapy for febrile children. *Evid Based Child Health* 9:730–732
- 619 137. Offringa M, Newton R, Cozijnsen MA, Nevitt SJ (2017) Prophylactic drug
620 management for febrile seizures in children. *Cochrane Database of Systematic*
621 *Reviews*. <https://doi.org/10.1002/14651858.CD003031.pub3>
- 622 138. Rosenbloom E, Finkelstein Y, Adams-Webber T, Kozier E (2013) Do antipyretics
623 prevent the recurrence of febrile seizures in children? A systematic review of
624 randomized controlled trials and meta-analysis. *European Journal of Paediatric*
625 *Neurology* 17:585–588
- 626 139. Mewasingh LD (2014) Febrile seizures. *BMJ Clin Evid* 2014:
- 627 140. Murata S, Okasora K, Tanabe T, et al (2018) Acetaminophen and Febrile Seizure
628 Recurrences During the Same Fever Episode. *Pediatrics*.
629 <https://doi.org/10.1542/peds.2018-1009>
- 630 141. Arana A, Morton NS, Hansen TG (2001) Treatment with paracetamol in infants. *Acta*
631 *Anaesthesiol Scand* 45:20–29
- 632 142. Ziesenitz VC, Zutter A, Erb TO, van den Anker JN (2017) Efficacy and Safety of
633 Ibuprofen in Infants Aged Between 3 and 6 Months. *Pediatric Drugs* 19:277–290
- 634 143. Gupta P, Sachdev HPS (2003) Safety of oral use of nimesulide in children: systematic
635 review of randomized controlled trials. *Indian Pediatr* 40:518–531
- 636 144. Aluka TM, Gyuse AN, Udonwa NE, Asibong UE, Meremikwu MM, Oyo-Ita A (2013)
637 Comparison of Cold Water Sponging and Acetaminophen in Control of Fever Among
638 Children Attending a Tertiary Hospital in South Nigeria. *J Family Med Prim Care*
639 2:153–158
- 640 145. Senz EH, Goldfarb DL (1958) Coma in a child following use of isopropyl alcohol in
641 sponging. *J Pediatr* 53:322–323
- 642 146. McFadden SW, Haddow JE (1969) Coma produced by topical application of
643 isopropanol. *Pediatrics* 43:622–623
- 644 147. Moss MH (1970) Alcohol-induced hypoglycemia and coma caused by alcohol
645 sponging. *Pediatrics* 46:445–447
- 646 148. Arditi M, Killner MS (1987) Coma following use of rubbing alcohol for fever control.
647 *Am J Dis Child* 141:237–238

- 648 149. Wise JR (1969) Alcohol sponge baths. *N Engl J Med* 280:840
- 649 150. Watts R, Robertson J (2012) Non-pharmacological Management of Fever in Otherwise
650 Healthy Children. *JBI Libr Syst Rev* 10:1634–1687
- 651 151. Purssell E (2000) Physical treatment of fever. *Arch Dis Child* 82:238–239
- 652 152. Thomas S, Vijaykumar C, Naik R, Moses PD, Antonisamy B (2009) Comparative
653 effectiveness of tepid sponging and antipyretic drug versus only antipyretic drug in the
654 management of fever among children: a randomized controlled trial. *Indian Pediatr*
655 46:133–136
- 656 153. Guppy MPB, Mickan SM, Mar CBD (2004) “Drink plenty of fluids”: a systematic
657 review of evidence for this recommendation in acute respiratory infections. *BMJ*
658 328:499–500
- 659 154. Martin DD (2016) Fever: Views in Anthroposophic Medicine and Their Scientific
660 Validity. *Evidence-Based Complementary and Alternative Medicine* 2016:1–13
- 661 155. Kinmonth AL, Fulton Y, Campbell MJ (1992) Management of feverish children at
662 home. *BMJ* 305:1134–1136
- 663 156. Gibson JP (1956) How much bed rest is necessary for children with fever? *The Journal*
664 *of Pediatrics* 49:256–261
- 665 157. Rabe A, Weiser M, Klein P (2004) Effectiveness and tolerability of a homoeopathic
666 remedy compared with conventional therapy for mild viral infections: Effectiveness
667 and Tolerability of Homoeopathic Remedy. *International Journal of Clinical Practice*
668 58:827–832
- 669 158. van Haselen R, Thinesse-Mallwitz M, Maidannyk V, Buskin SL, Weber S, Keller T,
670 Burkart J, Klement P (2016) The Effectiveness and Safety of a Homeopathic Medicinal
671 Product in Pediatric Upper Respiratory Tract Infections With Fever. *Glob Pediatr*
672 *Health*. <https://doi.org/10.1177/2333794X16654851>
- 673 159. Lyons N, Nejak D, Lomotan N, Mokszycki R, Jamieson S, McDowell M, Kulstad E
674 (2015) An alternative for rapid administration of medication and fluids in the
675 emergency setting using a novel device. *The American Journal of Emergency Medicine*
676 33:1113.e5–1113.e6
- 677 160. Tremayne V (2010) Emergency rectal infusion of fluid in rural or remote settings.
678 <https://web.a.ebscohost.com/abstract?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=13545752&AN=48329032&h=v1IVL0qBvq8mmA4VOif%2fK%2fBLm1kF6DP6ByiDDmGa2AID6nzeeef7mgBWUrUALz7AfXpbQ7hwzyASOebUmheEv g%3d%3d&crl=c&resultNs=AdminWebAuth&resultLocal=ErrCrlNotAuth&crlhashurl=login.aspx%3fdirect%3dtrue%26profile%3dehost%26scope%3dsite%26authtype%3dcrawler%26jrnl%3d13545752%26AN%3d48329032>. Accessed 23 May 2018

- 684 161. Dallimore J, Ebmeier S, Thayabaran D, Bellomo R, Bernard G, Schortgen F, Saxena
685 M, Beasley R, Weatherall M, Young P (2018) Effect of active temperature management
686 on mortality in intensive care unit patients. *Crit Care Resusc* 20:150–163
- 687 162. van Stuijvenberg M, Derksen-Lubsen G, Steyerberg EW, Habbema JDF, Moll HA
688 (1998) Randomized, Controlled Trial of Ibuprofen Syrup Administered During Febrile
689 Illnesses to Prevent Febrile Seizure Recurrences. *Pediatrics* 102:e51–e51
- 690 163. Brewer ET (1968) A comparative evaluation of indomethacin, acetaminophen and
691 placebo as antipyretic agents in children. *Arthritis & Rheumatism* 11:645–651
- 692 164. Chiappini E, Parretti A, Becherucci P, Pierattelli M, Bonsignori F, Galli L, de Martino
693 M (2012) Parental and medical knowledge and management of fever in Italian pre-
694 school children. *BMC Pediatr* 12:97
- 695 165. Bertille N, Fournier-Charrière E, Pons G, Chalumeau M (2013) Managing Fever in
696 Children: A National Survey of Parents' Knowledge and Practices in France. *PLoS*
697 *ONE* 8:e83469
- 698 166. Brick T, Agbeko RS, Davies P, et al (2017) Attitudes towards fever amongst UK
699 paediatric intensive care staff. *Eur J Pediatr* 176:423–427
- 700 167. Hay A, Redmond N, Costelloe C, Montgomery A, Fletcher M, Hollinghurst S, Peters T
701 (2009) Paracetamol and ibuprofen for the treatment of fever in children: the PITCH
702 randomised controlled trial. *Health Technology Assessment*.
703 <https://doi.org/10.3310/hta13270>
- 704 168. van den Anker JN (2013) Optimising the management of fever and pain in children. *Int*
705 *J Clin Pract Suppl* 26–32
- 706 169. Wright AD, Liebelt EL (2007) Alternating antipyretics for fever reduction in children:
707 an unfounded practice passed down to parents from pediatricians. *Clin Pediatr (Phila)*
708 46:146–150
- 709 170. Li SF, Lacher B, Crain EF (2000) Acetaminophen and ibuprofen dosing by parents.
710 *Pediatric Emergency Care* 16:394
- 711 171. Kearns RD, Conlon KM, Matherly AF, Chung KK, Bebartha VS, Hansen JJ, Cancio LC,
712 Peck M, Palmieri TL (2016) Guidelines for Burn Care Under Austere Conditions:
713 Introduction to Burn Disaster, Airway and Ventilator Management, and Fluid
714 Resuscitation. *J Burn Care Res* 37:e427-439
- 715 172. Carassiti M, Pumpo AD, Agrò FE (2013) Fluid Management in Palliative Care. In:
716 *Body Fluid Management*. Springer, Milano, pp 195–203
- 717 173. Bruera E, Pruvost M, Schoeller T, Montejo G, Watanabe S (1998) Proctoclysis for
718 Hydration of Terminally Ill Cancer Patients. *Journal of Pain and Symptom*
719 *Management* 15:216–219

- 720 174. Peck M, Jeng J, Moghazy A (2016) Burn Resuscitation in the Austere Environment.
721 Crit Care Clin 32:561–565
- 722 175. Nelson BD, Collins LB, Pritchard EWJ (2015) Innovations in Low- and Middle-
723 Income Countries for Newborn and Child Health. In: Innovating for Healthy
724 Urbanization. Springer, Boston, MA, pp 19–40
- 725 176. Rouhani S, Meloney L, Ahn R, Nelson BD, Burke TF (2011) Alternative Rehydration
726 Methods: A Systematic Literature Review and Lessons for Resource-Limited Care.
727 Pediatrics peds.2010-0952
- 728 177. Lozynsky OA, Dupuis L, Shandling B, Gilmour RF, Zimmerman B (1986)
729 Anaphylactoid and systemic reactions following saline enema administration. Six case
730 reports. Ann Allergy 56:62–66
- 731 178. Grocott MPW, McCorkell S, Cox ML (2005) Resuscitation From Hemorrhagic Shock
732 Using Rectally Administered Fluids in a Wilderness Environment. Wilderness &
733 Environmental Medicine 16:209–211
- 734 179. Hamre HJ, Glockmann A, Fischer M, Riley DS, Baars E, Kiene H (2007) Use and
735 Safety of Anthroposophic Medications for Acute Respiratory and Ear Infections: A
736 Prospective Cohort Study. Drug Target Insights 2:209–219
- 737 180. Bornhöft G, Matthiessen P (2011) Homeopathy in Healthcare: Effectiveness,
738 Appropriateness, Safety, Costs. Springer Science & Business Media
- 739 181. Hamre HJ, Glockmann A, Heckenbach K, Matthes H (2017) Use and Safety of
740 Anthroposophic Medicinal Products: An Analysis of 44,662 Patients from the EvaMed
741 Pharmacovigilance Network. Drugs - Real World Outcomes 4:199–213
- 742 182. American Academy of Pediatrics, Council on Communications and Media C on CA
743 (2013) Policy statement: Children, Adolescents, and the Media. Pediatrics 132:958–961
- 744 183. Andersson MA (2016) Chronic Disease at Midlife: Do Parent-child Bonds Modify the
745 Effect of Childhood SES? Journal of health and social behavior 57:373–389
- 746 184. Gunduz S, Usak E, Koksall T, Canbal M (2016) Why Fever Phobia Is Still Common?
747 Iran Red Crescent Med J 18:e23827
- 748 185. Bertille N, Purssell E, Corrad F, Chiappini E, Chalumeau M (2016) Fever phobia 35
749 years later: did we fail? Acta Paediatrica 105:9–10

Figure 1

Threshold for Antipyresis

Figure 2

Figure 3